Ultragenyx to Participate in Panel at Citi’s 16th Annual BioPharma Healthcare Conference
Rhea-AI Summary
On September 1, 2021, Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that CEO Emil D. Kakkis will speak at Citi's 16th Annual BioPharma Healthcare Conference on September 9, 2021, at 4:10 PM ET. The panel, titled Finding a Needle in a Haystack - Drug Development Strategies for Rare Disease, focuses on innovative approaches to developing therapies for rare genetic conditions. A live and archived webcast of the presentation will be available on the company's website for 90 days.
Ultragenyx is committed to addressing unmet medical needs in rare diseases through efficient drug development.
Positive
- None.
Negative
- None.
News Market Reaction – RARE
In the trading session that priced this news, RARE gained 1.83%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President will participate in a panel titled Finding a Needle in a Haystack - Drug Development Strategies for Rare Disease on Thursday, September 9, 2021 at Citi’s 16th Annual BioPharma Healthcare Conference at 4:10 PM ET.
The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-475-6370
